Retatrutide (LY3437943) is the first triple GLP-1/GIP/glucagon agonist approached in a phase 3 clinical trial. With a reduction in body weight reaching 24% in phase 2 studies, it surpasses in efficacy all molecules known to date in obesity research.
Tesamorelin is a synthetic analog of GHRH (Growth Hormone-Releasing Hormone) with a prolonged half-life, approved by the FDA under the name Egrifta for visceral lipoatrophy. Its precise mechanism of action on the GH/IGF-1 axis and its robust clinical data make it a reference compound for research on visceral adipose metabolism.
Three generations of incretin agonist peptides, three levels of efficacy, three differentiating mechanisms. This in-depth comparison analyzes the clinical and preclinical data of each molecule to guide the choice of research protocols in 2025-2026.
From first-generation GLP-1 to triple agonist Retatrutide, via GH fragments like AOD-9604: a complete overview of peptides studied for weight management, their mechanisms and the state of research.
